Commissioner of Insurance; conduct a comprehensive review of prescription drug pricing and identify strategies to reduce the cost of prescription medications; urge
House Resolution 1794 is a nonbinding resolution that urges the Georgia Commissioner of Insurance to conduct a comprehensive review of prescription drug pricing in the state and identify strategies to reduce the cost of prescription medications for Georgia residents. The resolution frames prescription drug costs as a growing burden on patients, families, employers, and public health programs, and links high prices to reduced medication adherence and worse health outcomes.
The resolution also emphasizes the need for greater transparency across the pharmaceutical supply chain, including manufacturers, pharmacy benefit managers, insurers, and other stakeholders. It points to approaches used in other states, such as all-payer claims data, advisory panels, and reporting requirements, as models for understanding pricing trends and developing policy solutions. The Commissioner is asked to evaluate insurance market practices, claims data, and pricing structures affecting drug costs.
The resolution further requests that the Commissioner submit a report of findings and recommendations to the Governor, the President of the Senate, and the Speaker of the House. Because it is a resolution rather than a statute, it does not itself change Georgia law or impose direct regulatory requirements; instead, it seeks an administrative review and policy recommendations that could inform future legislation or executive action.
Overall, the sentiment reflected in the bill text is strongly supportive of action to address prescription drug affordability and transparency. There is no recorded committee transcript or vote history in the provided context, so no formal opposition is documented here. The main policy tension implied by the resolution is between calls for increased oversight and transparency versus the interests of pharmaceutical companies, insurers, and pharmacy benefit managers that may be affected by such scrutiny.
HR 1794 does not amend the Georgia Code or create enforceable duties; it is a House resolution directing an inquiry and recommending a report. Its practical effect would be to prompt the Commissioner of Insurance to review prescription drug pricing and related insurance-market practices, potentially generating data and recommendations that could support future legislation, regulatory changes, or consumer-protection measures affecting patients, insurers, pharmacy benefit managers, and drug manufacturers.
The overall sentiment is favorable and reform-oriented. The resolution presents prescription drug affordability as a significant problem and expresses confidence that a state-level review can identify ways to improve transparency and lower costs. No votes or committee discussion are provided, so there is no evidence of recorded opposition or amendment activity in the supplied materials.
The bill itself does not identify explicit opponents, but the likely points of contention are the scope of state scrutiny over prescription drug pricing and the transparency obligations that could follow from the review. Stakeholders such as pharmaceutical manufacturers, pharmacy benefit managers, and insurers may resist increased disclosure or policy changes that could affect pricing practices, while supporters are likely to include consumer advocates, patients, employers, and public health interests seeking lower drug costs and better access to medications.